Exenatide
Also referenced as: Byetta, Bydureon BCise, Exendin-4 analogue
A synthetic exendin-4 analogue used in approved type 2 diabetes medicines.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved formulations treat type 2 diabetes; age eligibility and safety differ between Byetta and Bydureon BCise, the latter including patients aged 10 and older.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A synthetic exendin-4 analogue used in approved type 2 diabetes medicines.
FDA-approved formulations treat type 2 diabetes; age eligibility and safety differ between Byetta and Bydureon BCise, the latter including patients aged 10 and older.
Formulations are not interchangeable, and glycemic efficacy is not approval for general weight-loss use.
Why It's Being Studied
- Type 2 diabetes
- GLP-1 signalling
Mechanism of Action
It activates GLP-1 receptors to support glucose-dependent insulin secretion and affect gastrointestinal and appetite signalling.
It activates GLP-1 receptors to support glucose-dependent insulin secretion and affect gastrointestinal and appetite signalling. Formulations are not interchangeable, and glycemic efficacy is not approval for general weight-loss use.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Type 2 diabetes
- GLP-1 signalling
- Subcutaneous approved formulations
Evidence Summary
Controlled human trials support glycemic effects in labeled populations; immediate- and extended-release products have distinct evidence and age criteria.
Higher tiers carry more weight. Filled tiers have evidence for Exenatide; tap to read it.
- Controlled human trials support glycemic effects in labeled populations; immediate- and extended-release products have distinct evidence and age criteria.
2 cited sources.
- Prescribing label2
Human clinical evidence
- Controlled human trials support glycemic effects in labeled populations; immediate- and extended-release products have distinct evidence and age criteria.
Reported Adverse Events in Research
- Gastrointestinal effects, pancreatitis and kidney adverse effects matter; extended-release labeling includes a thyroid C-cell tumor warning.
Limitations of Current Evidence
- Formulations are not interchangeable, and glycemic efficacy is not approval for general weight-loss use.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Exenatide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved formulations | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Exenatide — prescribing label
- Prescribing label
BYDUREON BCISE prescribing sources